who invented glp-1 drugs History of glucagon-like peptide-1 receptor agonists The Future of GLP-1 Drugs

Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported more frequently in patients receiving semaglutide compared to placebo in clinical trials, with an incidence of approximately two to three percent

Additionally, co-infection, such as with viral hepatitis, is common among the HIV-infected population and is known to decrease life expectancy (Sulkowski, 2008)

Nrf2 Mediates Redox Adaptations to Exercise

Margis, R., Dunand, C., Teixeira, F

For weight management specifically, Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the FDA-approved options

Sasaki and Iwata, 2007)